伊布替尼（PCI-32765）治疗慢性淋巴细胞白血病。
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
机构信息
Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006.
Abstract
B-cell receptor (BCR) signaling is essential for chronic lymphocytic leukemia (CLL) cell survival. Many kinases in the BCR signaling pathway are being studied as potential therapeutic targets. Ibrutinib (PCI-32765) is a novel first-in-class selective inhibitor of Bruton tyrosine kinase. Preclinical evidence suggests that ibrutinib inhibits CLL cell survival and proliferation and affects CLL cell migration and homing. Early clinical data in patients with CLL and non-Hodgkin lymphoma is encouraging. It is likely that ibrutinib and other drugs targeting the BCR pathway will become an integral component of CLL therapy.
摘要
B 细胞受体 (BCR) 信号转导对于慢性淋巴细胞白血病 (CLL) 细胞的存活至关重要。BCR 信号通路中的许多激酶正被研究作为潜在的治疗靶点。依鲁替尼（PCI-32765）是一种新型的首个布鲁顿酪氨酸激酶选择性抑制剂。临床前证据表明，依鲁替尼抑制 CLL 细胞的存活和增殖，并影响 CLL 细胞的迁移和归巢。在 CLL 和非霍奇金淋巴瘤患者中的早期临床数据令人鼓舞。依鲁替尼和其他靶向 BCR 通路的药物很可能成为 CLL 治疗的一个组成部分。
相似文献
1
Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.伊布替尼（PCI-32765）治疗慢性淋巴细胞白血病。
Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006.
2
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.布鲁顿酪氨酸激酶抑制剂 PCI-32765 可阻止慢性淋巴细胞白血病细胞在体外和体内的存活和组织归巢。
Blood. 2012 Feb 2;119(5):1182-9. doi: 10.1182/blood-2011-10-386417. Epub 2011 Dec 16.
3
Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.伊布替尼用于治疗慢性淋巴细胞白血病和套细胞淋巴瘤。
Drugs Today (Barc). 2014 Apr;50(4):291-300. doi: 10.1358/dot.2014.50.4.2133570.
4
Targeted therapy in chronic lymphocytic leukemia: past, present, and future.慢性淋巴细胞白血病的靶向治疗：过去、现在和未来。
Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004.
5
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.依鲁替尼：首个布鲁顿酪氨酸激酶的共价抑制剂。
Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51.
6
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.伊布替尼：一种新型布鲁顿酪氨酸激酶抑制剂，在慢性淋巴细胞白血病患者中具有显著疗效。
Leuk Lymphoma. 2013 Aug;54(8):1817-20. doi: 10.3109/10428194.2013.796049.
7
Ibrutinib: a paradigm shift in management of CLL.依鲁替尼：慢性淋巴细胞白血病治疗的范式转变。
Expert Rev Hematol. 2014 Dec;7(6):705-17. doi: 10.1586/17474086.2014.977862.
8
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.布鲁顿酪氨酸激酶抑制剂在B细胞恶性肿瘤中的研发与应用现状
Drugs Aging. 2017 Jul;34(7):509-527. doi: 10.1007/s40266-017-0468-4.
9
Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.伊布替尼治疗慢性淋巴细胞白血病患者中持续的 Janus 激酶信号：一项 I 期试验结果。
Cancer Med. 2019 Apr;8(4):1540-1550. doi: 10.1002/cam4.2042. Epub 2019 Mar 7.
10
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.选择性布鲁顿酪氨酸激酶抑制剂阿卡拉布替尼与依鲁替尼在慢性淋巴细胞白血病细胞中的比较。
Clin Cancer Res. 2017 Jul 15;23(14):3734-3743. doi: 10.1158/1078-0432.CCR-16-1446. Epub 2016 Dec 29.
引用本文的文献
1
Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia.慢性淋巴细胞白血病患者重新使用伊布替尼后成功控制乙肝病毒再激活
Case Rep Hematol. 2021 Oct 21;2021:1862446. doi: 10.1155/2021/1862446. eCollection 2021.
2
Myeloma Bone Disease: A Comprehensive Review.多发性骨髓瘤骨病：全面综述。
Int J Mol Sci. 2021 Jun 8;22(12):6208. doi: 10.3390/ijms22126208.
3
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.针对 RET 驱动型癌症：不断发展的临床前和临床领域的经验教训。
Nat Rev Clin Oncol. 2018 Mar;15(3):151-167. doi: 10.1038/nrclinonc.2017.175. Epub 2017 Nov 14.
4
Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.依鲁替尼与MDM-2抑制剂协同作用，促进B细胞慢性淋巴细胞白血病的细胞毒性。
Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.
5
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.布鲁顿酪氨酸激酶抑制剂及其在治疗 B 细胞恶性肿瘤中的临床潜力：以伊布替尼为例。
Ther Adv Hematol. 2014 Aug;5(4):121-33. doi: 10.1177/2040620714539906.
6
Bone disease in multiple myeloma: pathophysiology and management.多发性骨髓瘤中的骨病：病理生理学与管理
Cancer Growth Metastasis. 2014 Aug 10;7:33-42. doi: 10.4137/CGM.S16817. eCollection 2014.
7
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.BTK 抑制剂时代的慢性淋巴细胞白血病的免疫治疗。
Leukemia. 2014 Mar;28(3):507-17. doi: 10.1038/leu.2013.311. Epub 2013 Oct 25.
本文引用的文献
1
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.激酶靶向策略在慢性淋巴细胞白血病中的新作用。
Blood. 2012 Dec 6;120(24):4684-91. doi: 10.1182/blood-2012-05-423194. Epub 2012 Aug 8.
2
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.苯达莫司汀联合利妥昔单抗治疗初治慢性淋巴细胞白血病患者：德国慢性淋巴细胞白血病研究组的一项多中心 II 期试验。
J Clin Oncol. 2012 Sep 10;30(26):3209-16. doi: 10.1200/JCO.2011.39.2688. Epub 2012 Aug 6.
3
The B-cell receptor signaling pathway as a therapeutic target in CLL.B 细胞受体信号通路作为 CLL 的治疗靶点。
Blood. 2012 Aug 9;120(6):1175-84. doi: 10.1182/blood-2012-02-362624. Epub 2012 Jun 19.
4
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.选择性新型脾酪氨酸激酶（Syk）抑制剂可抑制慢性淋巴细胞白血病 B 细胞的激活和迁移。
Leukemia. 2012 Jul;26(7):1576-83. doi: 10.1038/leu.2012.24. Epub 2012 Feb 7.
5
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.布鲁顿酪氨酸激酶抑制剂 PCI-32765 可阻止慢性淋巴细胞白血病细胞在体外和体内的存活和组织归巢。
Blood. 2012 Feb 2;119(5):1182-9. doi: 10.1182/blood-2011-10-386417. Epub 2011 Dec 16.
6
Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.培育与天性：慢性淋巴细胞白血病的微环境。
Hematology Am Soc Hematol Educ Program. 2011;2011:96-103. doi: 10.1182/asheducation-2011.1.96.
7
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.氟达拉滨联合阿仑单抗与氟达拉滨单药治疗既往治疗的慢性淋巴细胞白血病患者：一项随机 3 期试验。
Lancet Oncol. 2011 Dec;12(13):1204-13. doi: 10.1016/S1470-2045(11)70242-X. Epub 2011 Oct 10.
8
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.苯达莫司汀联合利妥昔单抗治疗复发/难治性慢性淋巴细胞白血病患者：德国慢性淋巴细胞白血病研究组的一项多中心 II 期试验。
J Clin Oncol. 2011 Sep 10;29(26):3559-66. doi: 10.1200/JCO.2010.33.8061. Epub 2011 Aug 15.
9
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.磷酸肌醇 3-激酶 δ 抑制剂 CAL-101 抑制慢性淋巴细胞白血病中 B 细胞受体信号和趋化因子网络。
Blood. 2011 Sep 29;118(13):3603-12. doi: 10.1182/blood-2011-05-352492. Epub 2011 Jul 29.
10
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.来那度胺作为老年慢性淋巴细胞白血病患者的初始治疗。
Blood. 2011 Sep 29;118(13):3489-98. doi: 10.1182/blood-2011-03-339077. Epub 2011 Jul 1.
Zotero 插件